Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy.

Autor:	Buchbinder EI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA.; Harvard Medical School, Boston, MA., Pfaff KL; Department of Pathology, Brigham and Women's Hospital, Boston, MA.; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA., Turner MM; Department of Pathology, Brigham and Women's Hospital, Boston, MA.; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA., Manos M; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA., Ouyang O; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA., Ott PA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA.; Harvard Medical School, Boston, MA.; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA., Giobbie-Hurder A; Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA., Rodig SJ; Harvard Medical School, Boston, MA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA.; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA., Hodi FS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA.; Harvard Medical School, Boston, MA.; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA.
Jazyk:	angličtina
Zdroj:	Journal of immunotherapy (Hagerstown, Md. : 1997) [J Immunother] 2023 Jun 01; Vol. 46 (5), pp. 192-196. Date of Electronic Publication: 2023 May 01.
DOI:	10.1097/CJI.0000000000000470
Abstrakt:	Despite the wide use of immune checkpoint inhibition for the treatment of melanoma, the mechanisms leading to long-term stable disease are incompletely understood. Patients with metastatic melanoma who had received ipilimumab alone or ipilimumab plus nivolumab 2+years prior and attained at least 6 months of stable disease were identified. Positron emission tomography/computed tomography (PET/CT) was performed. Pretreatment and posttreatment biopsies of areas of stable disease were assessed for tumor, fibrosis, and inflammation. Seven patients underwent PET/CT and tissue biopsy. Fluorodeoxyglucose avid lesions on PET/CT ranged from no activity to an SUV of 22. In 6 patients, the residual stable lesions were composed of necrosis and fibrosis with a prominent pigment containing macrophages and no residual melanoma. In 1 patient, a nodal lesion demonstrated melanoma with active inflammation. In most patients with durable stable disease after treatment with ipilimumab or ipilimumab/nivolumab, residual lesions demonstrated predominantly necrosis and fibrosis consistent with resolving lesions. The presence of melanophages in these samples may suggest ongoing immune surveillance. One patient did demonstrate residual melanoma, indicating the need for ongoing monitoring of this patient population. (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu